| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V37195-1mg |
99.47% | ￥550.00 |
3 | - | - | - | - |
|
V37195-2mg |
99.47% | ￥790.00 |
5 | - | - | - | - |
|
V37195-5mg |
99.47% | ￥1180.00 |
4 | - | - | - | - |
|
V37195-10mg |
99.47% | ￥1530.00 |
3 | - | - | - | - |
|
V37195-25mg |
99.47% | ￥3170.00 |
3 | - | - | - | - |
|
V37195-50mg |
99.47% | ￥4650.00 |
3 | - | - | - | - |
|
V37195-100mg |
99.47% | ￥6630.00 |
2 | - | - | - | - |
|
V37195-500mg |
≥99% | ￥13300.00 |
货期：3-5天 | - | - | - | - |
|
| 靶点： | Topoisomerase II | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体内研究： | Aldoxorubicin hydrochloride (INNO-206) (10.8 mg/kg, i.v.) shows significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAGκ-1A tumor. Aldoxorubicin hydrochloride (INNO-206) shows a good safety profile at doses up to 260 mg/mL doxorubicin equivalents, and is able to induce tumor regressions in breast cancer, small cell lung cancer and sarcoma in phase I study. Aldoxorubicin hydrochloride (INNO-206) shows superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models. | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京